(Q37124882)

18 August 2017

1 reference

title

Treatment of chronic hepatitis B and the implications of viral resistance to therapy (English)

1 reference

18 August 2017

1 reference

1 reference

2

Heiner Wedemeyer

1 reference

18 August 2017

Stefan Mauss

1

1 reference

18 August 2017

language of work or name

1 reference

1 April 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

191-199

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.191

21 January 2018

Identifiers

DOI

10.1586/14787210.6.2.191

1 reference

18 August 2017

1 reference